Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Executed strategic agreement for Imeglimin with Roivant Sciences; potential for up to USD 600 million in regulatory and development milestone payments and sales-based payments plus…

Read this Press Release: Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…

Read this Press Release: Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference

Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…

Read this Press Release: Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019
Click here to show the previous slide Click here to show the next slide